Beta-blocker use and urothelial bladder cancer survival: a Swedish register-based cohort study

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Berdik C. Unlocking bladder cancer. Nature. 2017;551(7679):S34–S35.
   PubMed Web of Science ®Google Scholar
• Minoli M, Kiener M, Thalmann GN, et al. Evolution of urothelial bladder cancer in the context of molecular classifications. IJMS. 2020;21(16):5670.
   Web of Science ®Google Scholar
• Zhang Y, Hong Y-K, Zhuang D-W, et al. Bladder cancer survival nomogram: Development and validation of a prediction tool, using the SEER and TCGA databases. Medicine. 2019;98(44):e17725.
   PubMed Web of Science ®Google Scholar
• Wang W, Liu J, Liu L. Development and validation of a prognostic model for predicting overall survival in patients with bladder cancer: a SEER-based study. Front Oncol. 2021;11:692728.
   PubMed Web of Science ®Google Scholar
• Wang J, Wu Y, He W, et al. Nomogram for predicting overall survival of patients with bladder cancer: a population-based study. Int J Biol Markers. 2020;35(2):29–39.
   Web of Science ®Google Scholar
• Lu Y, Tao J. Diabetes mellitus and obesity as risk factors for bladder cancer prognosis: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2021;12:699732.
   PubMed Web of Science ®Google Scholar
• Matos T, Cufer T, Cervek J, et al. Prognostic factors in invasive bladder carcinoma treated by combined modality protocol (organ-sparing approach)11Accepted for publication 30 august 1999. Int J Radiat Oncol, Biol, Phys. 2000;46(2):403–409.
   PubMed Web of Science ®Google Scholar
• Kamoun A, de Reyniès A, Allory Y, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77(4):420–433.
   PubMed Web of Science ®Google Scholar
• Teleka S, Jochems SHJ, Häggström C, et al. Association between blood pressure and BMI with bladder cancer risk and mortality in 340,000 men in three swedish cohorts. Cancer Med. 2021;10(4):1431–1438.
   PubMed Web of Science ®Google Scholar
• Cacciamani GE, Ghodoussipour S, Mari A, et al. Association between smoking exposure, neoadjuvant chemotherapy response and survival outcomes following radical cystectomy: systematic review and meta-analysis. J Urol. 2020;204(4):649–660.
   PubMed Web of Science ®Google Scholar
• Hou L, Hong X, Dai M, et al. Association of smoking status with prognosis in bladder cancer: a meta-analysis. Oncotarget. 2017;8(1):1278–1289.
   PubMedGoogle Scholar
• Costanzo ES, Sood AK, Lutgendorf SK. Biobehavioral influences on cancer progression. Immunol Allergy Clin North Am. 2011;31(1):109–132.
   PubMed Web of Science ®Google Scholar
• Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res. 2012;18(5):1201–1206.
   PubMed Web of Science ®Google Scholar
• Quốc Lu'o'ng KV, Nguyễn LTH. The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms. Cancer Manag Res. 2012;4:431–445.
   PubMedGoogle Scholar
• Archer M, Dogra N, Dovey Z, et al. Role of α- and β-adrenergic signaling in phenotypic targeting: significance in benign and malignant urologic disease. Cell Commun Signal. 2021;19(1):78.
   PubMed Web of Science ®Google Scholar
• Mravec B, Horvathova L, Hunakova L. Neurobiology of cancer: the role of β-adrenergic receptor signaling in various tumor environments. IJMS. 2020;21(21):7958.
   Web of Science ®Google Scholar
• Barron TI, Connolly RM, Sharp L, et al. Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol. 2011;29(19):2635–2644.
   PubMed Web of Science ®Google Scholar
• Lemeshow S, Sorensen HT, Phillips G, et al. beta-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomarkers Prev. 2011;20(10):2273–2279.
   PubMed Web of Science ®Google Scholar
• Udumyan R, Montgomery S, Fang F, et al. Beta-blocker drug use and survival among patients with pancreatic adenocarcinoma. Cancer Res. 2017;77(13):3700–3707.
   PubMed Web of Science ®Google Scholar
• Johannesdottir SA, Schmidt M, Phillips G, et al. Use of ss-blockers and mortality following ovarian cancer diagnosis: a population-based cohort study. BMC Cancer. 2013;13:85.
   PubMed Web of Science ®Google Scholar
• Udumyan R, Montgomery S, Fang F, et al. Beta-blocker use and lung cancer mortality in a nationwide cohort study of patients with primary non–small cell lung cancer. Cancer Epidemiol Biomarkers Prev. 2020;29(1):119–126.
   PubMed Web of Science ®Google Scholar
• Choi CH, Song T, Kim TH, et al. Meta-analysis of the effects of beta blocker on survival time in cancer patients. J Cancer Res Clin Oncol. 2014;140(7):1179–1188.
   PubMed Web of Science ®Google Scholar
• Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol. 2011;29(19):2645–2652.
   PubMed Web of Science ®Google Scholar
• Botteri E, Munzone E, Rotmensz N, et al. Therapeutic effect of beta-blockers in triple-negative breast cancer postmenopausal women. Breast Cancer Res Treat. 2013;140(3):567–575.
   PubMed Web of Science ®Google Scholar
• Rains SL, Amaya CN, Bryan BA. Beta-adrenergic receptors are expressed across diverse cancers. Oncoscience. 2017;4(7-8):95–105.
   PubMedGoogle Scholar
• Barlow L, Westergren K, Holmberg L, et al. The completeness of the swedish cancer register: a sample survey for year 1998. Acta Oncol. 2009;48(1):27–33.
   PubMed Web of Science ®Google Scholar
• Wettermark B, Hammar N, Fored CM, et al. The new swedish prescribed drug register – opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726–735.
   PubMed Web of Science ®Google Scholar
• Alfred Witjes J, Lebret T, Compérat EM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017;71(3):462–475.
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the swedish national inpatient register. BMC Public Health. 2011;11:450.
   PubMed Web of Science ®Google Scholar
• Statistics_Sweden. Longitudinal integration database for health insurance and labour market studies (LISA). Available from: https://www.scb.se/lisa-en/.
   Google Scholar
• Brooke HL, Talback M, Hornblad J, et al. The Swedish cause of death register. Eur J Epidemiol. 2017;32(9):765–773.
   PubMed Web of Science ®Google Scholar
• Royston P, Sauerbrei W. Multivariable modeling with cubic regression splines: a principled approach. Stata J. 2007;7(1):45–70.
   Web of Science ®Google Scholar
• Paul L. STPM2_STANDSURV: stata module to obtain standardized survival curves after fitting an STPM2 survival model. S458289 ed: MS, USA: Boston College Department of Economics; 2017.
   Google Scholar
• Sjölander A. Regression standardization with the R package stdReg. Eur J Epidemiol. 2016;31(6):563–574.
   PubMed Web of Science ®Google Scholar
• Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata J. 2009;9(2):265–290.
   Web of Science ®Google Scholar
• Clark TG, Bradburn MJ, Love SB, et al. Survival analysis part I: basic concepts and first analyses. Br J Cancer. 2003;89(2):232–238.
   PubMed Web of Science ®Google Scholar
• Radkiewicz C, Edgren G, Johansson ALV, et al. Sex differences in urothelial bladder cancer survival. Clin Genetourin Cancer. 2020;18(1):26–34.
   PubMed Web of Science ®Google Scholar
• Prout GR, Jr Wesley MN, Yancik R, et al. Age and comorbidity impact surgical therapy in older bladder carcinoma patients. Cancer. 2005;104(8):1638–1647.
   PubMed Web of Science ®Google Scholar
• Guancial EA, Roussel B, Bergsma DP, et al. Bladder cancer in the elderly patient: challenges and solutions. Clin Interv Aging. 2015;10:939–949.
   PubMed Web of Science ®Google Scholar
• Watkins JL, Thaker PH, Nick AM, et al. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer. 2015;121(19):3444–3451.
   PubMed Web of Science ®Google Scholar
• Flaig TW, Spiess PE, Agarwal N, et al. NCCN guidelines (R) Insights bladder cancer, version 5.2018. J Natl Compr Canc Netw. 2018;16(9):1041–1053.
   PubMed Web of Science ®Google Scholar
• Cole SW, Nagaraja AS, Lutgendorf SK, et al. Sympathetic nervous system regulation of the tumour microenvironment. Nat Rev Cancer. 2015;15(9):563–572.
   PubMed Web of Science ®Google Scholar
• Spera G, Fresco R, Fung H, et al. Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study. Ann Oncol. 2017;28(8):1836–1841.
   PubMed Web of Science ®Google Scholar
• Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. JAmCollCardiol. 2006;48(11):2258–2262.
   Web of Science ®Google Scholar
• Yun S, Vincelette ND, Abraham I. Cardioprotective role of beta-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis. Postgrad Med J. 2015;91(1081):627–633.
   PubMed Web of Science ®Google Scholar
• Pasquier E, Street J, Pouchy C, et al. Beta-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma. BrJCancer. 2013;108(12):2485–2494.
   Web of Science ®Google Scholar
• Zaravinos A, Volanis D, Lambrou GI, et al. Role of the angiogenic components, VEGFA, FGF2, OPN and RHOC, in urothelial cell carcinoma of the urinary bladder. Oncol Rep. 2012;28(4):1159–1166.
   PubMed Web of Science ®Google Scholar
• Zachos I, Konstantinopoulos PA, Tzortzis V, et al. Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise. Expert Opin Investig Drugs. 2010;19(7):875–887.
   PubMed Web of Science ®Google Scholar
• Tang J, Li Z, Lu L, et al. beta-adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy. Semin Cancer Biol. 2013;23(6 Pt B):533–542.
   PubMed Web of Science ®Google Scholar
• Tiligada E. Chemotherapy: induction of stress responses. Endocr Relat Cancer. 2006;13(Suppl 1):S115–S124.
   PubMed Web of Science ®Google Scholar
• Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol. 2005;144(3):317–322.
   PubMed Web of Science ®Google Scholar
• Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, et al. Beta-adrenergic receptors in cancer: therapeutic implications. Oncol Res. 2010;19(1):45–54.
   PubMed Web of Science ®Google Scholar
• Nagaraja AS, Sadaoui NC, Lutgendorf SK, et al. β-blockers: a new role in cancer chemotherapy? Expert Opin Investig Drugs. 2013;22(11):1359–1363.
   PubMed Web of Science ®Google Scholar
• Fitzgerald PJ. Beta blockers, norepinephrine, and cancer: an epidemiological viewpoint. Clin Epidemiol. 2012;4:151–156.
   PubMedGoogle Scholar
• Danaei G, Tavakkoli M, Hernan MA. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol. 2012;175(4):250–262.
   PubMed Web of Science ®Google Scholar
• Horwitz RI, Viscoli CM, Berkman L, et al. Treatment adherence and risk of death after a myocardial infarction. Lancet. 1990;336(8714):542–545.
   PubMed Web of Science ®Google Scholar
• Sturmer T, Glynn RJ, Rothman KJ, et al. Adjustments for unmeasured confounders in pharmacoepidemiologic database studies using external information. Med Care. 2007;45(10 Supl 2):S158–S165.
   PubMed Web of Science ®Google Scholar
• Mehio-Sibai A, Feinleib M, Sibai TA, et al. A positive or a negative confounding variable? A simple teaching aid for clinicians and students. Ann Epidemiol. 2005;15(6):421–423.
   PubMed Web of Science ®Google Scholar
• Andell P, Erlinge D, Smith JG, et al. beta-blocker use and mortality in COPD patients after myocardial infarction: a swedish nationwide observational study. J Am Heart Assoc. 2015;4(4):e001611.
   PubMed Web of Science ®Google Scholar
• Jansen L, Hoffmeister M, Arndt V, et al. Stage-specific associations between beta blocker use and prognosis after colorectal cancer. Cancer. 2014;120(8):1178–1186.
   PubMed Web of Science ®Google Scholar
• Schuller HM, Tithof PK, Williams M, et al. The tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a beta-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via beta-adrenergic receptor-mediated release of arachidonic acid. Cancer Res. 1999;59(18):4510–4515.
   PubMed Web of Science ®Google Scholar